Residency · Residency · Preventive Medicine

Pharmaceutical Policy and Drug Pricing

Overview

The United States has the highest pharmaceutical spending per capita of any nation, at approximately $1,400 per person per year. Drug pricing is shaped by a complex interplay of patent law, FDA regulation, insurer negotiations, and pharmacy benefit management. Pharmaceutical costs are a major driver of healthcare spending growth and a leading cause of medication non-adherence. Policy levers for cost containment are actively debated and evolving, most notably including the Inflation Reduction Act (2022) provisions authorizing Medicare drug price negotiation for the first time.

The Drug Development and Approval Pipeline

FDA Approval Pathways

The standard pathway for novel pharmaceuticals is the New Drug Application (NDA), requiring Phase I through III clinical trials. Biological products such as monoclonal antibodies, vaccines, and gene therapies require a Biologics License Application (BLA). The 505(b)(2) pathway allows reliance on existing data for modified versions of previously approved drugs. Accelerated Approval permits approval for serious conditions based on surrogate endpoints, with confirmatory trials required post-approval. Breakthrough Therapy Designation provides expedited development and review for drugs demonstrating substantial improvement over existing treatments. Fast Track designation enables frequent FDA meetings and rolling review for drugs addressing unmet needs. Priority Review shortens the review timeline to 6 months compared to the standard 10 months for drugs offering significant therapeutic advances.

Post-Market Surveillance

Phase IV studies provide ongoing safety monitoring after approval. The FDA Adverse Event Reporting System (FAERS) collects reports of adverse drug reactions. Risk Evaluation and Mitigation Strategies (REMS) are required for drugs with significant safety concerns and may include restricted distribution or mandatory patient registries. The FDA can require label changes, restrict distribution pathways, or withdraw approval entirely based on post-market safety signals.

Patent Law and Market Exclusivity

Patent Protections

Pharmaceutical patents typically last 20 years from the filing date. Patent term restoration under the Hatch-Waxman Act of 1984 extends patent life to compensate for time lost during the FDA review process. "Evergreening" strategies involve filing additional patents on formulations, delivery systems, metabolites, or dosing regimens to extend the effective period of exclusivity beyond the original patent. Patent thickets — multiple overlapping patents covering a single product — create complex legal barriers to generic entry.

Regulatory Exclusivity (Separate from Patents)

Regulatory exclusivity operates independently of patents. New Chemical Entity exclusivity provides 5 years of market protection. Orphan Drug exclusivity grants 7 years for drugs treating rare diseases affecting fewer than 200,000 patients. Pediatric exclusivity provides an additional 6 months for manufacturers who conduct requested pediatric studies. Biosimilar exclusivity grants 12 years for reference biologics, with biosimilar approval applications permitted after 4 years. New Clinical Investigation exclusivity provides 3 years for new indications of already-approved drugs.

Generic and Biosimilar Entry

The Hatch-Waxman Act of 1984 established the Abbreviated New Drug Application (ANDA) pathway for generic drugs. Generics must demonstrate bioequivalence to the reference drug but do not need to repeat clinical trials. Paragraph IV certifications allow generic manufacturers to challenge patents before their expiration. The first-to-file generic receives 180 days of marketing exclusivity. Biosimilars are biological products that are highly similar to an approved reference biologic with no clinically meaningful differences. Interchangeable biosimilars can be substituted at the pharmacy without requiring prescriber intervention. Biosimilar uptake in the U.S. has been slower than generic uptake due to manufacturing complexity, physician hesitancy, and aggressive patent litigation by originator manufacturers.

Drug Pricing Mechanisms

How Drug Prices Are Set

Manufacturers set the list price — known as the Wholesale Acquisition Cost (WAC) — unilaterally. Unlike most other high-income countries, the U.S. has no government price controls for most drugs. Pricing is often based on perceived "value" (clinical benefit and competitor pricing) rather than production costs. Launch prices for specialty and orphan drugs have escalated dramatically, with many exceeding $100,000 per year.

Pharmacy Benefit Managers (PBMs)

PBMs serve as intermediaries between drug manufacturers, insurers, and pharmacies. They negotiate rebates with manufacturers in exchange for favorable formulary placement. They manage formularies, prior authorization requirements, step therapy protocols, and tiered cost-sharing structures. The three largest PBMs — CVS Caremark, Express Scripts, and OptumRx — control approximately 80% of the market. The rebate system has been criticized for its opacity; rebates negotiated by PBMs may not translate to lower costs at the patient level, and spread pricing practices have drawn regulatory scrutiny.

The Drug Supply Chain

The pharmaceutical supply chain flows from manufacturer to wholesaler/distributor to pharmacy to patient, with multiple intermediaries — PBMs, insurers, and hospital purchasers — each adding markups and negotiating discounts at various points. The 340B Drug Pricing Program requires manufacturers to provide outpatient drugs at discounted prices to covered entities serving low-income patients. Covered entities include FQHCs, disproportionate share hospitals, and Ryan White clinics. The program has grown substantially but controversy exists about whether savings consistently reach patients.

Policy Levers for Cost Containment

Inflation Reduction Act (IRA, 2022)

The IRA authorized CMS to negotiate prices for select high-cost Medicare drugs for the first time. Ten drugs were selected for initial negotiation with negotiated prices taking effect in 2026, expanding to 20 drugs in subsequent years. Small molecule drugs become eligible after 9 years on market and biologics after 13 years. The Act established a $2,000 annual out-of-pocket cap for Medicare Part D beneficiaries effective 2025. Inflation rebates require manufacturers to pay rebates if drug prices increase faster than inflation for drugs covered by Medicare and Medicaid. A $35 per month insulin cap applies to Medicare beneficiaries.

International Reference Pricing

International reference pricing would tie U.S. drug prices to prices paid in other countries. A Most-Favored-Nation model was proposed but not fully implemented. Such policies would significantly reduce U.S. prices but face strong pharmaceutical industry opposition.

Importation

Allowing importation of drugs from countries with lower prices, primarily Canada, has been pursued by Florida and other states under federal waivers. Safety and supply concerns have limited implementation.

Formulary and Utilization Management

Tools include step therapy (requiring trial of lower-cost alternatives first), prior authorization, and tiered formularies. Value-based formularies place drugs based on clinical effectiveness relative to cost. Reference pricing sets a fixed insurer payment amount, with patients responsible for any difference when choosing higher-cost options.

Value-Based Pricing Frameworks

The Institute for Clinical and Economic Review (ICER) provides independent assessments of drug value. Professional organizations including ASCO and NCCN have developed value frameworks assessing clinical benefit relative to cost and toxicity. Outcomes-based contracts allow manufacturers to refund costs if drugs do not achieve pre-specified clinical outcomes in real-world use.

Impact on Public Health and Health Equity

High drug prices are a major driver of medication non-adherence — approximately 25% of U.S. adults report cost-related non-adherence, directly causing preventable morbidity and mortality. The impact falls disproportionately on low-income, uninsured, and minority populations. Specialty drug spending for conditions like cancer, autoimmune diseases, and rare diseases is the fastest-growing category of pharmaceutical expenditure. Generic drugs account for approximately 90% of prescriptions filled but only about 20% of total spending. The Orphan Drug Act, while successfully incentivizing rare disease drug development, has been exploited in some cases for repurposing common drugs for rare indications to gain exclusivity protections.

<image>A flow diagram showing the pharmaceutical supply chain from drug manufacturer to patient. The chain includes: manufacturer (sets WAC/list price) -> wholesaler/distributor -> pharmacy, with PBMs negotiating between manufacturers and insurers. Insurers/health plans set formulary tiers and cost-sharing. The patient pays copays/coinsurance at the pharmacy. Arrows show the flow of drugs, money, and rebates. Key intermediaries and their roles are annotated. Health policy education illustration.</image>

<image>A bar chart comparing pharmaceutical spending per capita across high-income countries (United States, Switzerland, Germany, Canada, France, Japan, UK, Australia). The U.S. bar is significantly taller than all others. An inset pie chart shows the breakdown of U.S. drug spending by category: specialty drugs, brand-name drugs, and generic drugs. Pharmaceutical policy education infographic.</image>

<image>A timeline showing the major U.S. pharmaceutical policy milestones: Hatch-Waxman Act (1984), Orphan Drug Act (1983), Medicare Part D (2003), Biologics Price Competition and Innovation Act (2009), 340B program expansion, and Inflation Reduction Act drug pricing provisions (2022). Each milestone includes a brief description of its impact on drug pricing and access. Clean health policy timeline illustration.</image>

Clinical Pearls

The 340B program is one of the most important but least understood drug pricing programs — it provides substantial discounts to safety-net providers, though controversy persists about whether savings consistently benefit patients. Cost-related medication non-adherence affects approximately 25% of U.S. adults and is a direct cause of preventable morbidity and mortality that clinicians should actively screen for. The IRA Medicare drug price negotiation program is historic but limited in scope, applying only to Medicare and only to a small number of drugs initially. Biosimilar adoption in the U.S. lags significantly behind Europe, and physician and patient education is needed to increase uptake and realize potential cost savings. For board preparation, understand the difference between patents and regulatory exclusivity, the role of PBMs in the drug supply chain, and the key provisions of the Inflation Reduction Act.

References

• Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316(8):858-871.
• Sarpatwari A, Avorn J, Kesselheim AS. State initiatives to control medication costs -- can transparency legislation help? N Engl J Med. 2016;374(24):2301-2304.
• Congressional Budget Office. Prescription Drugs: Spending, Use, and Prices. CBO; 2022.
• Dafny L, et al. The role of pharmacy benefit managers in drug pricing. JAMA. 2019;321(20):1966-1967.
• Inflation Reduction Act of 2022, Pub. L. No. 117-169.

Read this lecture as Markdown